Imaging with 68Ga-PSFA in patients with specific cancer markers
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
EARLY_PHASE1 · First Affiliated Hospital of Chongqing Medical University · NCT06387381
This study is testing a new imaging agent to see if it can help find cancer spots in patients with certain cancer markers.
Quick facts
| Phase | EARLY_PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | First Affiliated Hospital of Chongqing Medical University (other) |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT06387381 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the safety and effectiveness of a new imaging agent, 68Ga-PSFA, which targets both PSMA and FAP receptors in patients with suspected or diagnosed malignancies. The study aims to evaluate how well this dual receptor PET radiotracer can identify lesions in patients with PSMA/FAP positive diseases. Participants will undergo PET imaging to assess the biodistribution of the radiotracer and its potential utility in clinical diagnosis.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with suspected or diagnosed malignancies that express PSMA or FAP.
Not a fit: Patients with non-malignant diseases or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could enhance the accuracy of diagnosing certain cancers, leading to better treatment planning.
How similar studies have performed: While this approach is innovative, similar studies using targeted PET imaging agents have shown promise in the past.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. At least 18 years of age. 2. Signed informed consent. 3. Patients with suspected or newly diagnosed or previously malignant disease, with either PSMA or FAP positive expression (supporting evidence may include MRI, CT, and pathology report, etc). Exclusion Criteria: 1. Patients with non-malignant disease. 2. Patients with pregnancy. 3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent. 4. Known or expected hypersensitivity to 68Ga-PSFA or any of its components. 5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Where this trial is running
Chongqing, Chongqing Municipality
- The First Affiliated Hospital of Chongqing Medical University — Chongqing, Chongqing Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Xiaoyang Zhang, PhD
- Email: zhangxy@mail.bnu.edu.cn
- Phone: 86 023-89011755
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: PSMA, FAP, Positron-Emission Tomography